|
JP5589165B2
(ja)
|
2003-01-31 |
2014-09-17 |
マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー |
タンパク質欠損性障害の治療のための併用療法
|
|
MX351004B
(es)
|
2006-05-16 |
2017-09-26 |
Nat Institutes Of Health |
Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
|
|
US9999618B2
(en)
|
2007-04-26 |
2018-06-19 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
|
WO2009102895A2
(en)
|
2008-02-12 |
2009-08-20 |
Amicus Therapeutics, Inc. |
Method to predict response to pharmacological chaperone treatment of diseases
|
|
JP5616336B2
(ja)
|
2008-06-26 |
2014-10-29 |
オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ |
酵素活性の調節因子としてのＨｓｐ７０の使用
|
|
US8321148B2
(en)
|
2008-10-24 |
2012-11-27 |
Amicus Therapeutics, Inc. |
Multiple compartment dosing model
|
|
WO2010056746A1
(en)
*
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
GB0906159D0
(en)
*
|
2009-04-09 |
2009-05-20 |
Summit Corp Plc |
Drug combination for the treatment of proteostatic diseases
|
|
JP5645918B2
(ja)
|
2009-04-09 |
2014-12-24 |
アミカス セラピューティックス インコーポレイテッド |
リソソーム蓄積障害の予防および／または治療方法
|
|
DK2490712T3
(en)
*
|
2009-10-19 |
2015-10-05 |
Amicus Therapeutics Inc |
PROCESS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY USING Pharmacological chaperones TO INCREASE ACTIVITY OF GANGLIOSIDASER
|
|
WO2011049737A1
(en)
|
2009-10-19 |
2011-04-28 |
Amicus Therapeutics, Inc. |
Novel compositions for preventing and/or treating lysosomal storage disorders
|
|
RU2015147509A
(ru)
|
2009-10-19 |
2019-01-14 |
Амикус Терапьютикс, Инк. |
Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
|
|
ES2600932T3
(es)
*
|
2009-10-27 |
2017-02-13 |
Erytech Pharma |
Composición para inducir una tolerancia inmunitaria específica
|
|
EP2502068B1
(en)
*
|
2009-11-17 |
2016-02-10 |
Baylor Research Institute |
Urinary triaosylceramide (gb3) as a marker of cardiac disease
|
|
MY192644A
(en)
*
|
2009-11-27 |
2022-08-29 |
Genzyme Corp |
An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
|
|
US8962564B2
(en)
|
2010-11-08 |
2015-02-24 |
Amicus Therapeutics, Inc. |
Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
|
|
US9662375B2
(en)
|
2010-11-30 |
2017-05-30 |
Orphazyme Aps |
Methods for increasing intracellular activity of Hsp70
|
|
WO2012125402A2
(en)
*
|
2011-03-11 |
2012-09-20 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of fabry disease
|
|
EP2533051A1
(en)
*
|
2011-06-06 |
2012-12-12 |
Centogene GmbH |
Method for the diagnosis of Gaucher's disease
|
|
KR20200032244A
(ko)
|
2012-03-07 |
2020-03-25 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
MX354127B
(es)
|
2012-03-27 |
2018-02-14 |
Amicus Therapeutics Inc |
Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
|
|
RS61598B1
(sr)
*
|
2012-05-03 |
2021-04-29 |
Amicus Therapeutics Inc |
Režimi doziranja za tretman pompeove bolesti
|
|
EP2874648A4
(en)
|
2012-07-17 |
2015-12-30 |
Amicus Therapeutics Inc |
ALPHA GALACTOSIDASE A AND 1-DEOXYGALACTONO JIRIMYCIN CO FORMULATION
|
|
US10155027B2
(en)
|
2012-07-17 |
2018-12-18 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
|
|
US9675627B2
(en)
|
2014-04-14 |
2017-06-13 |
Amicus Therapeutics, Inc. |
Dosing regimens for treating and/or preventing cerebral amyloidoses
|
|
US10709700B2
(en)
|
2014-09-15 |
2020-07-14 |
Orphazyme A/S |
Arimoclomol formulation
|
|
JP6851964B2
(ja)
|
2014-09-30 |
2021-03-31 |
アミカス セラピューティックス インコーポレイテッド |
炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
US10179128B2
(en)
*
|
2015-08-31 |
2019-01-15 |
Amicus Therapeutics, Inc. |
Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
|
|
US11613759B2
(en)
|
2015-09-04 |
2023-03-28 |
Sqz Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
IL299470B2
(en)
|
2015-12-30 |
2026-05-01 |
Amicus Therapeutics Inc |
Improved acid alpha-glucosidase for the treatment of Pompe disease
|
|
JP6438421B2
(ja)
*
|
2016-02-17 |
2018-12-12 |
ファナック株式会社 |
電動機のステータ
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
KR102618519B1
(ko)
|
2016-03-30 |
2023-12-28 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
재조합 산 알파-글루코시다제를 포함하는 제형
|
|
WO2017178029A1
(en)
|
2016-04-13 |
2017-10-19 |
Orphazyme Aps |
Heat shock proteins and cholesterol homeostasis
|
|
ES2831764T3
(es)
|
2016-04-29 |
2021-06-09 |
Orphazyme As |
Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
|
|
CN109415741A
(zh)
|
2016-05-03 |
2019-03-01 |
Sqz生物技术公司 |
细胞内递送生物分子以诱导耐受性
|
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
KR20190134807A
(ko)
|
2017-04-25 |
2019-12-04 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
중추 신경계의 퇴행성 질환 및/또는 리소솜 저장병을 예방 및/또는 치료하기 위한 신규한 조성물
|
|
CN119113091A
(zh)
|
2017-05-15 |
2024-12-13 |
阿米库斯治疗学公司 |
重组人类酸性α-葡萄糖苷酶
|
|
PL4062916T3
(pl)
|
2017-05-30 |
2025-03-17 |
Amicus Therapeutics, Inc. |
Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
|
|
AU2018277756A1
(en)
|
2017-05-30 |
2020-01-23 |
Amicus Therapeutics, Inc. |
Methods of treating fabry patients having renal impairment
|
|
EP4717319A3
(en)
|
2018-02-06 |
2026-06-10 |
Amicus Therapeutics, Inc. |
Methods of treating fabry disease in pregnant patients
|
|
LT3840753T
(lt)
|
2018-08-20 |
2024-11-11 |
Amicus Therapeutics, Inc. |
Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
|
|
EP3894864A2
(en)
*
|
2018-12-10 |
2021-10-20 |
Denali Therapeutics Inc. |
Lysosomal storage disorder biomarkers and methods of use thereof
|
|
US20220313670A1
(en)
*
|
2019-06-11 |
2022-10-06 |
Amicus Therapeutics, Inc. |
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
|
|
KR20220044560A
(ko)
|
2019-08-07 |
2022-04-08 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
|
|
EP4247792A1
(en)
|
2020-11-19 |
2023-09-27 |
Zevra Denmark A/S |
Processes for preparing arimoclomol citrate and intermediates thereof
|
|
US11623916B2
(en)
|
2020-12-16 |
2023-04-11 |
Amicus Therapeutics, Inc. |
Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
|
|
US20240197706A1
(en)
|
2022-12-13 |
2024-06-20 |
Amicus Therapeutics, Inc. |
Methods of improving the pharmacokinetics of migalastat
|